SCHEMBL13049764

SCHEMBL13049764

O=Cc1ccc(-c2oc3ccccc3c2CO)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ FTO Q9C0B1 1/20 0.42
▸ ACP1 P24666 2/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ DDR2 Q16832 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049762 0.85 MEN1 (0.43) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL2962849 0.82 KMT2A (0.53) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL13049706 0.81 PTPN1 (0.45) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL13049700 0.80 FBP1 (0.44) MEN1KMT2AALDH1A1MAPK1HPGD
SCHEMBL13080176 0.80 CYP3A4 (0.42) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL13049701 0.80 LMNA (0.57) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL13049703 0.77 PTGS2 (0.59) MEN1KMT2ACYP3A4ALDH1A1ALOX15
SCHEMBL13049719 0.77 CYP19A1 (0.55) MEN1KMT2ACYP3A4ALDH1A1ALOX15
SCHEMBL13049721 0.77 MAPK14 (0.49) PTPN1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL13049759 0.77 CYP19A1 (0.52) PTPN1MEN1KMT2ACYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 PTPN1 4473/4885MEN1 1513/4885KMT2A 4355/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 PTPN1 4345/4885MEN1 1254/4885KMT2A 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback